Skip to content

Study · Randomized controlled trial · n = 30 · 1996

5 results

Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.

Raderer M, Becherer A, Kurtaran A, Angelberger P, Li S, Leimer M, Weinlaender G, Kornek G, Kletter K, Scheithauer W, Virgolini I

Journal of nuclear medicine : official publication, Society of Nuclear Medicine1 Sept 1996Cited by 5 (Europe PMC)

PMID8790198 (opens in a new tab)PepBankPUB-08790198
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with intestinal adenocarcinomas, 123I-VIP scans were true-positive in 28 of 30 patients (93%) versus 17 of 30 patients (56%) with 111In-CYT-103.

    In plain wordsIn people with bowel cancer, the VIP tracer scan found cancer in 93% of patients, compared with 56% for the antibody tracer scan.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableTrue-positive 123I-VIP scans in intestinal adenocarcinoma patients
    Study

    n = 30

    Comparator
    111In-CYT-103 (anti-TAG-72 antibody) scan
    Outcome group
    Diagnostic imaging · Cancer
    Studied dose
    150-200 MBq; 1 microgramAs given in this study (human).

    Measurements

    True-positive scans
    28 of 30 patients
    123I-VIP
    True-positive scans
    93%
    123I-VIP

    Source sentences

    Summary
    In total, 123I-VIP scans were true-positive in 28 of 30 patients (93%) versus 17 of 30 patients administered 111In-CYT-103 (56%).
    2 context sentences
    Summary · context
    In this study, we have compared the in vitro and in vivo binding of 123I-VIP and of the 111In-labeled monoclonal antibody (MAb) directed against TAG-72 (OncoScint; 111In-CR-103) in patients with intestinal adenocarcinomas in a single-blinded, prospectively randomized trial.
    Summary · context
    Twenty patients were administered either 123I-VIP (150-200 MBq; 1 microgram) or 111In-CYT-103 (150 MBq; 1 mg) for one imaging study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Liver metastases were visualized in five of six patients by 123I-VIP receptor scanning and in four of these patients with 111In-CYT-103.

    In plain wordsIn six patients with liver metastases, the VIP tracer scan showed them in five. The antibody tracer scan showed them in four.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicable123I-VIP imaging of liver metastases
    Study

    n = 6

    Comparator
    111In-CYT-103 (anti-TAG-72 antibody) scan
    Outcome group
    Diagnostic imaging · Cancer
    Studied dose
    150-200 MBq; 1 microgramAs given in this study (human).

    Source sentences

    Summary
    Liver metastases were visualized in five of six patients by 123I-VIP receptor scanning and in four of these patients with 111In-CYT-103.
    1 context sentence
    Summary · context
    After interim analysis demonstrated superior imaging with 123I-VIP, the next 10 patients (accounting for a total of 50 patients) enrolled in this trial underwent both studies in random order to allow for a direct comparison.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In a subgroup scanned with both agents, primary intestinal adenocarcinomas were imaged in five of five patients with 123I-VIP and in only two of these patients with 111In-CYT-103.

    In plain wordsIn five patients with primary bowel cancer, the VIP tracer scan imaged all five tumours. The antibody tracer scan imaged only two.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicable123I-VIP imaging of primary intestinal adenocarcinomas
    Study

    n = 5

    Comparator
    111In-CYT-103 (anti-TAG-72 antibody) scan
    Outcome group
    Diagnostic imaging · Cancer
    Studied dose
    150-200 MBq; 1 microgramAs given in this study (human).

    Source sentences

    Summary
    In the subgroup of 10 patients enrolled in the second part of the study, primary intestinal adenocarcinomas were imaged in five of five patients with 123I-VIP and in only two of these patients with 111In-CYT-103.
    1 context sentence
    Summary · context
    After interim analysis demonstrated superior imaging with 123I-VIP, the next 10 patients (accounting for a total of 50 patients) enrolled in this trial underwent both studies in random order to allow for a direct comparison.
  4. 04LabEx vivo tissueActivity measurement

    In vitro, 123I-VIP showed significant binding to primary colorectal tumors.

    In plain wordsIn lab tests, the VIP tracer showed significant binding to samples of primary bowel tumours.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicable123I-VIP binding to primary colorectal tumors in vitro
    Study

    n: not reported in source

    Primary colorectal tumors (in vitro)
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The in vitro results indicated significant binding of 123I-VIP to primary colorectal tumors
  5. 05LabIn vitro (cells)Activity measurement

    In vitro, 123I-VIP showed significant binding to HT29 and COLO320 adenocarcinoma cells.

    In plain wordsIn cells, the VIP tracer showed significant binding to two bowel cancer cell lines.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicable123I-VIP binding to adenocarcinoma cell lines in vitro
    Study

    n: not reported in source

    HT29 and COLO320 adenocarcinoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The in vitro results indicated significant binding of 123I-VIP to primary colorectal tumors as well as to HT29 and COLO320 adenocarcinoma cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.